{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:16:48Z","timestamp":1785525408473,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108410","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:29:11Z","timestamp":1760138951000},"page":"108410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world outcomes after initiation of Elexacaftor\/tezacaftor\/ivacaftor in an adolescent cohort with cystic fibrosis"],"prefix":"10.1016","volume":"249","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9330-7102","authenticated-orcid":false,"given":"James R","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Donnelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-0290","authenticated-orcid":false,"given":"Jennie","family":"Louise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-3868","authenticated-orcid":false,"given":"Jodi","family":"Grunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"La Vanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.rmed.2025.108410_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108410_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"Supplement_2","key":"10.1016\/j.rmed.2025.108410_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J. Pediatric. Infect. Dis. Soc."},{"issue":"19","key":"10.1016\/j.rmed.2025.108410_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108410_bib5","series-title":"Landmark PBS Listing for Australians with Cystic Fibrosis [Internet]","year":"2022"},{"key":"10.1016\/j.rmed.2025.108410_bib6","article-title":"Age-based pediatric growth reference charts","author":"Shypailo","year":"2020","journal-title":"Baylor Coll. Med. Children's Nutr. Res. Center Body Compos. Lab. Web Site"},{"issue":"4","key":"10.1016\/j.rmed.2025.108410_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jac5.1771","article-title":"Research and scholarly methods: measuring medication adherence","volume":"6","author":"Shah","year":"2023","journal-title":"J. Am. Coll. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.rmed.2025.108410_bib8","first-page":"1","article-title":"The R package geepack for generalized estimating equations","volume":"15","author":"H\u00f8jsgaard","year":"2005","journal-title":"J. Stat. Soft."},{"key":"10.1016\/j.rmed.2025.108410_bib9","article-title":"Emmeans: estimated marginal means, aka least-squares means","author":"Lenth","year":"2024","journal-title":"R package version 1.10.2"},{"issue":"5","key":"10.1016\/j.rmed.2025.108410_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10212","key":"10.1016\/j.rmed.2025.108410_bib11","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rmed.2025.108410_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.rmed.2025.108410_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with Elexacaftor\/Tezacaftor\/Ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108410_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28508","article-title":"Real-world effectiveness of elexacaftor\/tezacaftor\/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis","volume":"10","author":"Keens","year":"2024","journal-title":"Heliyon"},{"issue":"24","key":"10.1016\/j.rmed.2025.108410_bib15","first-page":"S2213","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"9","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108410_bib16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jcf.2023.06.003","article-title":"Body composition and body mass index measures from 8 to 18 years old in children with cystic fibrosis","volume":"22","author":"Tran","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2025.108410_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2025.108410_bib18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"8","key":"10.1016\/j.rmed.2025.108410_bib19","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ppul.26485","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on lung disease in cystic fibrosis","volume":"58","author":"Gushue","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2025.108410_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2025.102345","article-title":"Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis","volume":"88","author":"Sheikh","year":"2025","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.rmed.2025.108410_bib21","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.3389\/fmicb.2018.02419","article-title":"Staphylococcus aureus Nasal colonization: an update on mechanisms, epidemiology, risk factors, and subsequent infections","volume":"9","author":"Sakr","year":"2018","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108410_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00519-24","article-title":"Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis","volume":"15","author":"Armbruster","year":"2024","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.rmed.2025.108410_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.rmed.2025.108410_bib24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1164\/rccm.202305-0844LE","article-title":"Cell-free DNA detects Pseudomonas aeruginosa lung infection in modulator-treated people with cystic fibrosis","volume":"208","author":"Long","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108410_bib25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jcf.2023.02.010","article-title":"Exhaled breath profiles to detect lung infection with Staphylococcus aureus in children with cystic fibrosis","volume":"22","author":"Licht","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.108410_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2025.108410_bib27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108410_bib28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.rmed.2025.108410_bib29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.108410_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","article-title":"Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?","volume":"21","author":"Granger","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.108410_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241235054","article-title":"Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor\u2013tezacaftor\u2013ivacaftor combination: a 1-year observational study","volume":"18","author":"Blardone","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108410_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/pch\/13.1.19","article-title":"Adherence to treatment in adolescents","volume":"13","author":"Taddeo","year":"2008","journal-title":"Paediatr. Child Health"},{"issue":"6","key":"10.1016\/j.rmed.2025.108410_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jcf.2010.08.016","article-title":"Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF","volume":"9","author":"George","year":"2010","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2025.108410_bib35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ppul.21195","article-title":"Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis","volume":"45","author":"Dziuban","year":"2010","journal-title":"Pediatr. Pulmonol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108410_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/scs.70106","article-title":"Mapping perceived impact, facilitators and barriers of cystic fibrosis management in children and adolescents: a qualitative study from the parents' perspective","volume":"39","author":"Gagulic","year":"2025","journal-title":"Scand. J. Caring Sci."},{"key":"10.1016\/j.rmed.2025.108410_bib37","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/PPA.S136890","article-title":"An upper and lower bound of the medication possession ratio","volume":"30","author":"Sperber","year":"2017","journal-title":"Patient Prefer. Adherence"},{"issue":"1","key":"10.1016\/j.rmed.2025.108410_bib38","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"BioMed Res. Int."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:06:15Z","timestamp":1763690775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125004731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S0954611125004731"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108410","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes after initiation of Elexacaftor\/tezacaftor\/ivacaftor in an adolescent cohort with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108410"}}